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Influence of different formulations and process parameters 
 during the preparation of drug-loaded PLGA microspheres 
evaluated by multivariate data analysis
The main objective of this study was to evaluate the influ-
ence of the formulation and process parameters on PLGA 
microparticles containing a practically insoluble model 
drug (ibuprofen) prepared by the o/w solvent evaporation 
method. Multivariate data analysis was used. The effects of 
altered stirring speed of a mechanical stirrer (600, 1000 
rpm), emulsifier concentrations (PVA concentration 0.1 %, 
1 %) and solvent selection (dichloromethane, ethyl acetate) 
on microparticle characteristics (encapsulation efficiency, 
drug loading, burst effect) were observed. It was found that 
with increased stirring speed, the PVA concentration or the 
use of ethyl acetate had a significantly negative effect on 
encapsulation efficiency. In addition, ethyl acetate had an 
adverse effect on the burst effect, while increased stirring 
speed had the opposite effect. Drug load was not affected 
by any particular variable, but rather by the interactions of 
evaluated variables.
Keywords: solvent evaporation, encapsulation, PLGA, con-
trolled release, burst effect
In the last decade, poly(lactic-co-glycolic acid) (PLGA) received great interest in the 
medical and pharmaceutical field because of its biodegradability, toxicological safety and 
desirable biocompatibility. It is one of the small number of synthetic polymers that has 
been approved by the FDA for human clinical use. Nowadays, PLGA is widely applied in 
controlled drug delivery systems, including nano- and micro-particles and implants (1). 
PLGA-based microparticles are well established as advanced drug delivery systems, al-
lowing drug protection and controlled release upon parenteral administration (2). PLGA 
microspheres are considered to be an important carrier for the encapsulation of water-in-
soluble drug candidates in the early stages of drug development (3). They offer various 
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accurately control the drug release kinetics over a period of days to months; (ii) complete 
biodegradability (avoiding the removal of empty remnants upon drug exhaust); (iii) good 
biocompatibility, even within brain tissue (4, 5). However, the design of this type of ad-
vanced drug delivery system is not straightforward, because many factors influence the 
resulting drug release rate from PLGA microparticles, including the method of prepara-
tion. One of the most common methods of preparing PLGA microparticles is the single 
emulsion solvent evaporation method, which consists of four major steps: (i) dissolution or 
dispersion of the bioactive compound in an organic solvent containing the matrix-forming 
polymer; (ii) emulsification of this organic phase in a second, continuous (frequently aque-
ous) phase immiscible with the first phase; (iii) extraction of the solvent from the dispersed 
phase by the continuous phase, which is optionally accompanied by solvent evaporation 
transforming the droplets into solid microspheres; (iv) harvesting and drying of micro-
spheres (6). The first two steps primarily affect the microparticle size distribution while 
the last two steps determine the microparticle morphology and have an important influ-
ence on the microparticle encapsulation and release behavior (7).
The main objective of the experiment was to prepare drug-loaded PLGA microspheres 
containing practically insoluble ibuprofen (IBU), which served as the model drug. Several 
formulation and process parameters of the oil in water (o/w) single emulsion method were 
modified, such as alteration of the stirring speed during solvent evaporation, emulsifier 
concentration and the type of organic solvent to enhance ibuprofen encapsulation. The 
main section is devoted to the expression of the statistical significance of the above-men-
tioned formulation and process parameters on PLGA particle characteristics, such as 
shape and size, encapsulation efficacy and in vitro drug release. The full factorial design 
method and partial least squares PLS-2 regression were regarded the best methods for 
evaluating the impact of parameters that were otherwise difficult to compare.
EXPERIMENTAL
Materials
Ibuprofen (Zentiva, Czech Republic) was the model drug, PLGA Resomer® RG 504 S 
(Boehringer Ingelheim, Pharma GmbH & Co, Germany) was used as the polymer carrier. 
Dichloromethane (DM, Penta, Czech Republic) and ethyl acetate (EA, Dr. Kulich Pharma, 
Czech Republic) were used as solvents and polyvinylalcohol (PVA) served as emulsifier. A 
phosphate buffer at pH 6.8 (dodecahydrate sodium hydrogenphosphate, potassium dihy-
drogenphosphate, both Merck KGaA, Germany) was applied as the dissolution medium. 
All materials were of Ph. Eur. quality.
Sample preparation
Drug-loaded PLGA microparticles were prepared by the o/w solvent evaporation 
method. In order to form an o/w-type emulsion, 150 mg of the drug and 700 mg of the 
polymer were dissolved in 5 mL of either dichloromethane or ethyl acetate. The solution 
was homogenized for 1 minute using an Ultra-Turrax (T25 basic, IKA-Werke, Germany) at 
20,000 rpm for one minute to dissolve the polymer completely and then it was emulsified 
all at once into 800 mL of the aqueous continuous phase containing either 0.1 % (m/m) or 
405
J. Vysloužil et al.: Influence of different formulations and process parameters during the preparation of drug-loaded PLGA micro-
spheres evaluated by multivariate data analysis, Acta Pharm. 64 (2014) 403–417.
 
1 % (m/m) PVA. The emulsion was stirred with a mechanical stirrer with a pitched-blade 
impeller (Heidolph RZR 2021, Sigma Aldrich, USA) at either 600 or 1000 rpm for 2 hours to 
ensure complete solvent evaporation. The prepared microparticles were collected on a fine 
mesh sieve with 80 μm-sized openings, washed three times with purified water and dried 
at 25 °C in a cabinet drier (HORO–048B, Dr. Hofmann GmbH, Germany) for 24 h before 
further testing. All samples were prepared in triplicate and marked according to the al-
tered parameters: DM/ET stands for organic solvent (dichloromethane or ethyl acetate), 
L/H expresses low or high PVA concentration and 600/1000 determines the stirring speed 
per minute. Sample characteristics are shown in Table I.
Table I. Variables in the preparation of microparticle samples
Sample Organic solvent PVA concentration (%) Stirring speed (rpm)
DM-L-600 DM 0.1 600
DM-L-1000 DM 0.1 1000
EA-L-600 EA 0.1 600
EA-L-1000 EA 0.1 1000
DM-H-600 DM 1 600
DM-H-1000 DM 1 1000
EA-H-600 EA 1 600
EA-H-1000 EA 1 1000
Particle distribution
The size-based mean diameter and size distribution of the microparticles were mea-
sured with a laser diffraction particle size distribution analyzer (Horiba Partica LA-300, 
Horiba Ltd., Japan). 100 μL of a prediluted microparticle sample (0.5 g mL–1 of phosphate 
buffered saline) was injected into a cuvette-type fraction cell (filled with 10 mL of degassed 
and filtered phosphate buffered saline, pH 7.2) provided with a magnetic stirrer to prevent 
non-homogenous distribution due to the sedimentation of particles. All samples were 
measured immediately after the application into the cuvette and were analyzed for num-
ber-weighted size distribution.
Scanning electron microscopy
The morphology and surface topography of the microparticles were examined by 
scanning electron microscopy. The samples were mounted directly onto the SEM sample 
holder using double-sided tape and then coated with a 10-nm thick layer of gold powder 
and images were taken using a scanning electron microscope (MIRA3, Tescan, Czech Re-
public) at accelerating voltage of 5.0 kV.
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Drug content
Ibuprofen content in the drug loaded microparticles was determined by dissolving an 
appropriate amount of dried PLGA-based microparticles (~10 mg of ibuprofen) in 25 mL of 
an appropriate organic solvent (ethyl acetate or dichloromethane). The absorbance of sam-
ples was measured at 264 nm using a UV/Vis spectrometer (Lambda 25, Perkin Elmer, 
USA). Encapsulation efficiency (EE) and drug load (DL) were determined from the values 
obtained using the following equations (8, 9):





where cs corresponds to the actual ibuprofen content and ct corresponds to the theoretical 
drug load. The assay was carried out in triplicate and the results were expressed as mean 
values and standard deviations (SD).






where m1 is the drug mass in microparticles, m2 is the gross mass of microparticles. The 
assay was carried out in triplicate. The results are expressed as mean values and SD.
The effectiveness of the process was also evaluated by the yield, calculated by the fol-
lowing equation (10):





where m2 is the gross mass of microparticles, mt is the total mass of the drug and polymer 
used for microparticle preparation.
In vitro release studies
The in vitro release studies of drug-loaded beads were carried out using the paddle 
method in an automatic dissolution apparatus (SOTAX AT 7 On-Line System, Donau Lab, 
Switzerland) at 100 rpm. The dissolution medium volume used was 500 mL of phosphate 
buffer (pH 6.8) kept at 37.0 ± 0.5 °C. Samples were analyzed using a UV spectrophotometer 
(Lambda 25, Perkin Elmer, USA) at 264 nm. The samples for the dissolution test were weighed 
with respect to their encapsulation efficiency, so that 50 mg of ibuprofen was in each sample. 
The in vitro drug release was observed for 72 hours. The dissolution test was carried out with 
six samples of each batch and the results were expressed as average values and SD.
Similarity factor analysis
Similarity factor f2 was originally designed for dissolution profiles comparing the 
originals and the generics (11). It can be also used for the drug release profile comparison 
of samples prepared with different parameters. Similarity factor values ranged between 0 
and 100. If f2 ≥ 50, drug release profiles were over 90 % similar. If f2 < 50, release profiles 
were not similar and the observed influence of the formulation or process variables was 
considered to be significant. Standard deviations of the mean data did not exceed 9.1 %, so 
407
J. Vysloužil et al.: Influence of different formulations and process parameters during the preparation of drug-loaded PLGA micro-
spheres evaluated by multivariate data analysis, Acta Pharm. 64 (2014) 403–417.
 
the conditions for the variation (20 % maximum for the earlier points, 10 % maximum for 
the rest) were met. No more than one measurement was considered after 85 % of dissolu-
tion (12).
 f2 = 50 ´ log  (4)
Ri  – drug amount (%) released at time interval i; reference sample
Ti   – drug amount (%) released at time interval i; tested sample
n  – total number of samplings
Factorial design
The experiment was planned as a 22 full factorial design with three replicated mea-
surements, i.e., 12 data points (Table I), to evaluate the influence of several variables (PVA 
concentration, stirring speed) and their interaction with response variables (encapsulation 
efficiency, drug loading, burst effect value) for each solvent separately. Individual experi-
ments were performed in random order. The resulting data were analyzed by Unscrambler 
X (v. 1.3, Camo software) with the application of multiple linear regressions. For each re-
sponse variable, the results were expressed as the regression model in the form:
 Y = b0 + b1X1 + b2X2 + b12X1X2 + e (5)
where Y is the response variable, X1 to X3 are technological variables, β0 is a constant (in-
tercept), β1 to β12 are regression coefficients representing an individual effect or interaction, 
e is the residual, i.e., the difference between the observed and predicted values of Y. MLR 
models can be described on the basis of goodness-of-fit coefficients. R-square describes 
variability explained by the model, R-square of prediction expresses predictive ability of 
the model. C.V. (Coefficient of Variation) is the average modeling error expressed as per-
centage of the mean (13). Model significance was tested using ANOVA (Analysis of Vari-
ance); it was also used for evaluation of individual and interaction effects.
Analyzed data, including yield and particle size (Table I), were also evaluated by a 
principal component analysis (PCA) to study systematic variability and the relationships 
between variables and objects.
RESULTS AND DISCUSSION
Particle size and morphological properties
Effect of stirring speed. – The prepared microparticles with the mean size ranging be-
tween 90.7 to 382.8 μm showed particle size dependence on the stirring speed during 
solvent evaporation. The results in Table II confirmed that the microparticle mean size 
decreased with an increase in the stirring speed, which is a very well-documented effect 
(14, 15, 16). The force of higher stirring speed distributes the internal phase into smaller 
droplets, resulting in the formation of smaller microparticles (14).
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Table II. Characteristics of drug-loaded microparticles
Sample DL (%) EE (%) Yield (%) Mean size (μm) 
Initial drug release 
after 30 min (%)
DM-L-600 18.2 ± 0.1 79.8 ± 0.5 77.3 ± 5.1 382.8 20.0 ± 3.5
DM-L-1000 17.0 ± 0.3 57.4 ± 0.3 59.6 ± 5.2 254.9 23.6 ± 3.4
EA-L-600 17.5 ± 0.4 58.2 ± 1.6 40.7 ± 6.6 174.6   9.0 ± 3.9
EA-L-1000 16.2 ± 0.4 22.2 ± 1.4 24.2 ± 4.6 169.7 14.7 ± 3.9
DM-H-600 13.9 ± 0.5 44.6 ± 0.6 56.5 ± 5.0 284.3 18.0 ± 3.8
DM-H-1000 20.0 ± 2.4 23.2 ± 2.5 29.3 ± 6.2 173.5 29.1 ± 9.7
EA-H-600 19.0 ± 0.4 40.4 ± 0.4 54.0 ± 3.8   90.7   9.0 ± 3.5
EA-H-1000 17.5 ± 0.4 16.7 ± 0.5 16.8 ± 7.1 146.6   9.5 ± 0.8
Effect of PVA concentration. – It is also evident from Table II that particle size was de-
pendent on the external phase viscosity, as the increasing PVA concentration decreased 
particle size. The particle size of samples prepared with 0.1 % PVA ranged between 169.7 
and 382.8 μm, while the size of microparticles prepared with 1 % PVA had values from 90.7 
Fig. 1. Particle size distribution of PLGA (Resomer® RG 504S) microparticles prepared with dichloro-
methane as organic solvent: a) DM-L-600, b) DM-H-600, c) DM-L-1000, d) DM-H-1000.
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to 284.3 μm. Increased PVA concentration ensured better system stabilization against co-
alescence of the emulsion and therefore led to formation of smaller microparticles (17). 
Better emulsion stability also resulted in narrower particle size distribution in all samples, 
as seen in Figs. 1 and 2. Another well-observed effect (18) was that the value of the PVA 
concentration influenced also the shape of prepared microparticles. Fig. 3 shows that DM-
L-600 provided spherical microparticles with holes in the surface, while DM-H-600 gave 
compact, spherical, regular and more uniform microparticles.
Effect of the organic solvent choice. – As observed in Fig. 3 and Table II, microparticles 
prepared with dichloromethane provided regular, highly spherical microparticles with a 
smooth surface, characterized by larger particle size in contrast to the smaller, irregularly-
shaped microparticles created when ethyl acetate was used. A typical feature of ethyl ac-
etate microspheres is their rough surface. An explanation could be that the polarity of 
ethyl acetate is higher compared to dichloromethane, resulting in microparticles of lower 
quality (19).
Encapsulation process. – Drug loading of the prepared samples ranged between 13.9 
and 20.0 %, encapsulation efficiency had values from 16.7 to 79.8 % (Table II). For evaluation 
of the encapsulation process, i.e., influence of the parameters on encapsulation efficiency 
and drug loading, MLR models for both organic solvents were used separately, four mod-
els in all. Regression diagnostics of all models had very good values (R-square > 0.8, R-
square predicted > 0.8, C.V. < 3 %, models p < 0.001).
Fig. 2. Particle size distribution of PLGA (Resomer® RG 504S) microparticles prepared with ethyl 
ace tate as organic solvent: a) EA-L-600, b) EA-H-600, c) EA-L-1000, d) EA-H-1000.
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Plots of interactions were used to compare the influence of variables on the effect. They 
represent an average value of factor effect in dependence on the level of the second factor. In 
case of encapsulation efficiency for ethyl acetate samples (Fig. 4a), positive significance (p < 
0.001) of the PVA concentration-stirring speed interaction was found. The plot shows that the 
influence of PVA concentration depends on the stirring speed. On the other hand, results for 
dichloromethane samples reveal a significant effect of individual variables (p < 0.001 for 
both), as shown in Fig. 4b. Both connecting lines between the effect averages are parallel, i.e., 
for both PVA concentrations, the increase in stirring speed equals an approximately identi-
cal decrease in encapsulation efficiency. In case of both solvents, the maximum of encapsula-
tion efficiency was reached with lower PVA concentration and slower stirring speed, which 
is in agreement with the literature. Increase in the stirring speed delivers greater energy to 
the system, resulting in an increased breakdown of the forming microparticles and lower 
encapsulation efficiency (20). It was also found that an excessive increase of PVA concentra-
tion can lead to lower encapsulation efficiency, probably due to higher viscosity (21, 22). Of 
both solvents used, ethyl acetate was found to provide lower values for encapsulation effi-
ciency. Higher polarity of ethyl acetate, and therefore higher miscibility with the external 
phase, was probably responsible for the formation of a less stable o/w emulsion. In the EA/
PVA system, the drug is transferred to the external phase more frequently and a smaller 
number of microparticles is produced, resulting in lower encapsulation efficiency (23).
In case of drug loading in samples prepared with ethyl acetate (Fig. 5a), the significant 
effect of individual variables is obvious (p < 0.001). This means that for both PVA concentra-
Fig. 3. SEM photographs of the surface of PLGA microparticles corresponding to: a) DM-L-600, b) 
DM-H-600, c) EA-L-600, d) EA-H-600.
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tions an increase in stirring speed led to an equivalent decrease in drug loading. Maxi-
mum drug loading was achieved with a high PVA concentration and low stirring speed. 
In dichloromethane samples (Fig. 5b), the effect of PVA concentration-stirring speed inter-
action is apparent (p < 0.001). At lower PVA concentration, the influence of the stirring 
speed on drug loading is relatively low compared to higher PVA concentration, where an 
increase in the stirring speed greatly increases drug loading. However, drug loading does 
not reflect the loss rate of the encapsulation process and therefore it serves as a comple-
mentary characteristic to encapsulation efficiency.
Drug-release behavior of microparticles
Figs. 6 and 7 show the drug dissolution profiles performed at pH 6.8. The obtained 
release profiles were characterized as predominantly bi-phasic profiles with apparent 
burst release, followed by sustained drug release for at least 72 hours. The basic release 
pattern of PLGA microparticles is a tri-phasic profile. However, factors such as pore forma-
tion and/or closure, drug solubility, drug amount, and polymer molecular mass and/or its 
density can transform a tri-phasic profile into a bi-phasic one (24–26).
Burst effect. – MLR models for burst effect have good coefficients of determination, but 
predictive characteristic limits are reached due to greater variability between replicates. (R2 
> 0.75, R2 predicted < 0.5, C. V. < 18 %, model p-values: 0.05 < p < 0.1, i.e., possibly significant). 
Despite this fact, model plots provide sufficient representation of average factor effects and 
Fig. 4. Interaction plots; effect of PVA concentra-
tion on encapsulation efficiency, at various stir-
ring speeds, for: a) ethyl acetate, b) dichloro-
methane.
Fig. 5. Interaction plots; effect of PVA concentra-
tion on drug loading, at various stirring speeds, 
for: a) ethyl acetate, b) dichloromethane.
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models are used for approximate evaluation of the factors’ influence on the effects. In sam-
ples prepared with ethyl acetate, there was possibly a significant effect (0.05 < p < 0.1) of PVA 
concentration-stirring speed. At higher PVA concentration, the burst effect values were 
roughly the same for both stirring speeds used, whereas there was a remarkable difference 
at lower PVA concentration (Fig. 8a). Results of dichloromethane samples showed a signifi-
cant influence of individual variable stirring speed (p < 0.05) on the burst effect (Fig. 8b). At 
1000 rpm, the burst effect was at least six units greater than with samples prepared at 600 
rpm. At 1000 rpm, smaller microparticles were prepared and therefore these samples had a 
larger surface area per mass unit than samples prepared at 600 rpm. This effect resulted in 
a higher burst effect followed by faster drug release (22). The burst effect is generally consid-
ered to be undesirable, especially because of local or systemic toxicity and shortening of 
release profiles (27). However, in some cases, the burst effect can be advantageous, primar-
ily in wound treatment, targeted delivery or controlled release.
Sustained release. – Similar factor f2 analysis also revealed the dependence of drug re-
lease on the stirring speed in dichloromethane samples prepared with 1 % PVA concentra-
Fig. 6. In vitro dissolution profiles of ibuprofen from PLGA samples prepared with dichloromethane 
as organic solvent.
Fig. 7. In vitro dissolution profiles of ibuprofen from PLGA samples prepared with ethyl acetate as 
organic solvent.
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tion (DM-H-600 x DM-H-1000 f2 = 29.9) and in ethyl acetate samples prepared with 0.1 % 
PVA (ET-L-600 x ET-L-1000 f2 = 46.1). Ethyl acetate samples prepared with 1 % PVA and 
dichloromethane samples prepared with 0.1 % PVA were considered to be similar (ET-H-
600 x ET-H-1000 f2 = 64.3; DM-L-600 x DM-L-1000 f2 = 66.3) and therefore the stirring speed 
alone probably had no significant influence on drug release.
PVA concentration had a noticeable impact on drug release, as shown in Figs. 6 and 7. 
All the samples prepared with 0.1 % PVA concentration exhibited faster drug release than 
their equivalent counterparts prepared with 1 % PVA concentration (with the exception of 
DM-H-1000, which showed the fastest release among all samples). For example, DM-L-600 
released 67.1 % of IBU within 72 hours in comparison with DM-H-600, which released 40.0 
% of the drug. This is surprising, as higher PVA concentration helps produce smaller mi-
croparticles with a larger surface, just like the surfactant effect of the remaining PVA on 
the surface (22), and so faster drug release is to be expected. The explanation of this phe-
nomenon could be the more even distribution of the drug inside the matrix. Higher viscos-
ity of the 1 % PVA solution can significantly lower the concentration gradient of the drug 
inside the particles (17). The significance of this effect was evaluated by the similarity fac-
tor f2 analysis. Similarity factors f2 between samples prepared with 0.1 and 1 % PVA were 
determined. For ethyl acetate samples, the similarity factor f2 values were 30.2 (ET-L-600 x 
ET-H-600) and 25.7 (ET-L-1000 x ET-H-1000), which indicated that there was a significant 
dependence of the drug amount released on the PVA concentration. However, the dichlo-
romethane samples’ similarity factor f2 had values of 42.6 (DM-L-600 x DM-H-600) and 53.7 
(DM-L-1000 x DM-H-1000). This means that in dichloromethane samples, the dependence 
of drug release on emulsifier concentration disappears with the increase of rotation speed, 
confirming the multifactorial complexity of the process (24).
Fig. 8. Interaction plots; effect of PVA con-
centration on burst effect, at various stir-
ring speeds, for: a) ethyl acetate, b) dichlo-
romethane.
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Fig. 9. PCA bi-plot displays a projection of objects (boxes) and response variables (circles) in the area 
of the first two components. Objects describe the performed experiment in the form: solvent (DM-
dichloromethane; EA-ethyl acetate)-PVA concentration (L-low; H-high)-stirring speed (600; 1000). 
The first two components describe 77 % of total variability.
Fig. 10. PCA bi-plot displays a projection of objects (boxes) and response variables (circles) in the area 
of the first two components. Highly correlated variables from previous model (Fig. 9) were removed 
in order to take into account the remaining variability. Objects describe the performed experiment 
in the form: solvent (DM-dichloromethane; EA-ethyl acetate)-PVA concentration (L-low; H-high)-
stirring speed (600; 1000). The first two components describe 89 % of total variability.
Figs. 6 and 7 show drug release differences between ethyl acetate and dichlorometh-
ane samples. The ethyl acetate samples prepared with 0.1 % PVA concentration were char-
acterized by faster drug release than samples prepared with dichloromethane. This could 
be explained by the different distribution of IBU in the matrix of microparticles. In the DM 
samples with a perfectly spherical shape, the drug could be situated more in the periph-
eral matrix parts, resulting in higher burst effect. On the other hand, EA samples were 
smaller, deformed and collapsed, could have the drug spread out more evenly around the 
matrix. Although the behavior of samples was different, the similarity factor f2 between 
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the ethyl acetate and the dichloromethane samples did not confirm the significance of this 
variable (ET-L-600 x DM-L-600 f2 = 54.1; ET-L-1000 x DM-L-1000 f2 = 57.9). Faster release from 
the ethyl acetate samples negated the difference caused by lower burst effect.
However, at a 1 % PVA concentration, the subsequent drug release rate was approxi-
mately the same for both ethyl acetate and dichloromethane samples. This means that the 
curves remained parallel with a relatively wide gap. Similarity factor f2 analysis calculated 
between the EA and DM samples prepared with 1 % PVA revealed the significance of the 
solvent choice effect on dissolution profiles (ET-H-600 x DM-H-600 f2 = 43.0; ET-H-1000 × 
DM-H-1000 f2 = 22.7). Most likely, the higher PVA viscosity caused more evident differ-
ences in the dissolution profiles.
This interesting information was also obtained from the results of PCA analysis (Fig. 
9). From the position of the symbols representing response variables, it is apparent that 
there was a correlation among variables-encapsulation efficiency, yield and mean mic-
roparticle size. The practical benefit of this finding could be seen in approximate predic-
tion of these variables based on the knowledge of only one of them.
Another PCA model was designed for the study of variability among variables. High-
ly correlating variable encapsulation efficiency and yield were removed to prevent the 
overvaluation effect on the PC-1 component. This enabled a description of the mean size 
and initial drug release correlation (Fig. 10) and their influence on PC-1, at which the sol-
vent type variability lies. A strong influence of organic solvent on the mentioned variables 
was manifested. Dichloromethane gave double values compared to ethyl acetate.
CONCLUSIONS
PLGA microparticle samples were successfully prepared by the solvent evaporation 
method. The full factorial design method and partial least squares PLS-2 regression were used 
to evaluate the impact of several formulations and process parameters used during the pro-
cess.  It was found that the formulation and process parameters influenced the microparticle 
characteristics as individual variables but also in interactions with other parameters. Multi-
variate data analysis was shown to be an applicable tool for identification of such relations. 
The results confirm the complexity of the process using the solvent evaporation method.
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